New Delhi:Wockhardt Ltd has reported a strong turnaround in its quarterly performance, posting a consolidated profit after tax of Rs 82 crore for the second quarter ended September 30, 2025, compared to a loss of Rs 16 crore in the same period last year. However, the company’s revenue from operations declined to Rs 782 crore, compared with Rs 818 crore in the year-ago quarter,Wockhardtsaid in a statement. The company’s India business contributed Rs 172 crore during the quarter, reflecting a 3 per cent growth compared to the previous year, it added. The UK business generated Rs 313 crore, a growth of 4 per cent compared to the previous year, PTI reported. Besides, the Ireland business stood at Rs 59 crore in the second quarter with a growth of 40 per cent compared to the previous year, it added. "We see significant scale up and advancing our leadership in the Biotech diabetes segment on the back of new partnerships in the Emerging markets and India, entry into new markets like Russia and Malaysia as we commit to offer affordable Insulin globally,” it said. Read also:Wockhardt seeks USFDA approval for Zidebactam-Cefepime injection to treat Serious GramNegative Infections Read also:CDSCO Panel Asks Wockhardt to Revise Phase III Study Protocol for Nafithromycin, Seeks Dosing, Control Arm Changes
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!